ZA981080B - Bicyclic inhibitors of protein farnesyl transferase - Google Patents
Bicyclic inhibitors of protein farnesyl transferaseInfo
- Publication number
- ZA981080B ZA981080B ZA981080A ZA981080A ZA981080B ZA 981080 B ZA981080 B ZA 981080B ZA 981080 A ZA981080 A ZA 981080A ZA 981080 A ZA981080 A ZA 981080A ZA 981080 B ZA981080 B ZA 981080B
- Authority
- ZA
- South Africa
- Prior art keywords
- pct
- farnesyl transferase
- present
- protein farnesyl
- date aug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3750497P | 1997-02-11 | 1997-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA981080B true ZA981080B (en) | 1998-08-12 |
Family
ID=21894697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA981080A ZA981080B (en) | 1997-02-11 | 1998-02-10 | Bicyclic inhibitors of protein farnesyl transferase |
Country Status (13)
Country | Link |
---|---|
US (3) | US6133303A (xx) |
EP (1) | EP0966446B1 (xx) |
JP (1) | JP2001518076A (xx) |
KR (1) | KR20000070924A (xx) |
AT (1) | ATE307119T1 (xx) |
AU (1) | AU725696B2 (xx) |
BR (1) | BR9807674A (xx) |
CA (1) | CA2273895A1 (xx) |
DE (1) | DE69831937T2 (xx) |
ES (1) | ES2252827T3 (xx) |
NZ (1) | NZ336134A (xx) |
WO (1) | WO1998034921A1 (xx) |
ZA (1) | ZA981080B (xx) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6284755B1 (en) | 1998-12-08 | 2001-09-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2001251649A1 (en) * | 2000-04-17 | 2001-10-30 | Warner Lambert Company | Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
CA2405696A1 (en) * | 2000-04-17 | 2001-10-25 | Warner-Lambert Company | 5-substituted tetralones as inhibitors of ras farnesyl transferase |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
EP1539234A4 (en) * | 2002-09-05 | 2006-02-15 | Medimmune Inc | METHODS OF PREVENTING OR TREATING CELLULAR MALIGNITES BY ADMINISTERING CD2 ANTAGONISTS |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
EP2316487B1 (en) | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Recombinant IL-9 antibodies & uses thereof |
JP4934426B2 (ja) | 2003-08-18 | 2012-05-16 | メディミューン,エルエルシー | 抗体のヒト化 |
US7550482B2 (en) * | 2004-02-27 | 2009-06-23 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
US20060004001A1 (en) * | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
EP2422811A2 (en) | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
JP5153613B2 (ja) | 2005-03-18 | 2013-02-27 | メディミューン,エルエルシー | 抗体のフレームワーク・シャッフル |
KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
WO2007041697A2 (en) * | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
JP5209625B2 (ja) | 2006-08-28 | 2013-06-12 | 協和発酵キリン株式会社 | アンタゴニストのヒトlight特異的ヒトモノクローナル抗体 |
AU2008232902B2 (en) | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
KR101686247B1 (ko) | 2007-10-31 | 2016-12-14 | 메디뮨 엘엘씨 | 단백질 스캐폴드 |
BRPI0915467A2 (pt) * | 2008-07-10 | 2015-08-18 | Southern Res Inst | Compostos, composição farmacêutica, métodos de intensificação de eficácia de agente farmacológico e de triagem de compostos para uso como inibidores de mrp e respectivos usos |
US8725967B2 (en) * | 2008-08-08 | 2014-05-13 | Amazon Technologies, Inc. | Providing executing programs with access to stored block data of others |
DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
CN116574185A (zh) | 2012-07-25 | 2023-08-11 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
SG11201509982UA (xx) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
DK3041507T3 (da) | 2013-08-26 | 2021-07-26 | Biontech Res And Development Inc | Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR102614642B1 (ko) | 2014-06-04 | 2023-12-19 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 강글리오사이드 gd2에 대한 사람 단클론 항체 |
PT3333191T (pt) | 2014-12-11 | 2020-12-15 | Pf Medicament | Anticorpos anti-c10orf54 e suas utilizações |
BR112017015880A2 (pt) | 2015-03-03 | 2018-07-31 | Kymab Ltd | anticorpos, usos e métodos |
KR20180100122A (ko) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체 |
EP3909983A1 (en) | 2015-12-02 | 2021-11-17 | STCube & Co. Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
CN105801421A (zh) * | 2016-03-31 | 2016-07-27 | 常州大学 | 一种2-醛基-3-羟基-4,6-二氯苯甲酸的合成方法 |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
EP3635007A1 (en) | 2017-06-06 | 2020-04-15 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
EP3824287A1 (en) | 2018-07-20 | 2021-05-26 | Pierre Fabre Médicament | Receptor for vista |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH535225A (de) * | 1969-03-29 | 1973-03-31 | Schering Ag | Verfahren zur Herstellung von heterocyclischen Nitroverbindungen |
DE1937630A1 (de) * | 1969-07-19 | 1971-02-04 | Schering Ag | 2-(5-Nitro-2-furfuryliden)-l-tetralone |
JPS6013788A (ja) * | 1983-07-05 | 1985-01-24 | Yamanouchi Pharmaceut Co Ltd | 新規なクマリン誘導体 |
BR8305086A (pt) | 1983-09-19 | 1984-03-20 | Antonio Signori | Dispositivo de amortecimento aplicavel a calcados em geral |
ES8601148A1 (es) * | 1984-12-10 | 1985-11-16 | Ferrer Int | Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos. |
US5059609A (en) * | 1987-10-19 | 1991-10-22 | Pfizer Inc. | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases |
MX13485A (es) * | 1987-10-19 | 1993-05-01 | Pfizer | Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos |
GB2244431A (en) * | 1990-05-31 | 1991-12-04 | Farmos Oy | Treatment of age related memory impairment and other cognitive disorders |
US5149703A (en) * | 1991-09-06 | 1992-09-22 | Merck Frosst Canada, Inc. | Quinoline-substituted chromans and related compounds as leukotriene antagonists |
USRE37303E1 (en) * | 1992-01-10 | 2001-07-31 | Institut National Del La Sante Et De La Recherche Medicale | Imidazole compounds and their therapeutic applications |
CZ100095A3 (en) * | 1992-10-21 | 1995-11-15 | Pfizer | Sulfonamide derivatives of hydroxy substituted alicyclic or heterocyclic compounds with condensed benzene nucleus and pharmaceutical preparations based thereon |
US6075037A (en) * | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
EP0695753A1 (en) * | 1994-08-05 | 1996-02-07 | Zeneca Limited | Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use |
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
DE69627377T2 (de) * | 1995-11-06 | 2004-02-05 | University Of Pittsburgh | Inhibitoren der protein-isoprenyl-transferase |
WO1997027854A1 (en) * | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250460A1 (en) * | 1996-04-03 | 1997-10-09 | John H. Hutchinson | Inhibitors of farnesyl-protein transferase |
US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6127390A (en) * | 1997-10-02 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
JP2001520222A (ja) * | 1997-10-22 | 2001-10-30 | ゼネカ・リミテッド | イミダゾール誘導体およびファルネシルタンパク質トランスフェラーゼインヒビターとしてのそれらの使用 |
FR2787451B1 (fr) * | 1998-12-18 | 2001-01-26 | Adir | Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6143766A (en) * | 1999-04-16 | 2000-11-07 | Warner-Lambert Company | Benzopyranone and quinolone inhibitors of ras farnesyl transferase |
US6403581B1 (en) * | 2000-01-19 | 2002-06-11 | American Cyanamid Company | Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives |
-
1998
- 1998-02-10 ZA ZA981080A patent/ZA981080B/xx unknown
- 1998-02-11 ES ES98906491T patent/ES2252827T3/es not_active Expired - Lifetime
- 1998-02-11 NZ NZ336134A patent/NZ336134A/en unknown
- 1998-02-11 BR BR9807674-4A patent/BR9807674A/pt not_active IP Right Cessation
- 1998-02-11 JP JP53510598A patent/JP2001518076A/ja not_active Abandoned
- 1998-02-11 CA CA002273895A patent/CA2273895A1/en not_active Abandoned
- 1998-02-11 US US09/355,662 patent/US6133303A/en not_active Expired - Fee Related
- 1998-02-11 DE DE69831937T patent/DE69831937T2/de not_active Expired - Fee Related
- 1998-02-11 AU AU61704/98A patent/AU725696B2/en not_active Ceased
- 1998-02-11 KR KR1019997007189A patent/KR20000070924A/ko not_active Application Discontinuation
- 1998-02-11 EP EP98906491A patent/EP0966446B1/en not_active Expired - Lifetime
- 1998-02-11 AT AT98906491T patent/ATE307119T1/de not_active IP Right Cessation
- 1998-02-11 WO PCT/US1998/003025 patent/WO1998034921A1/en active IP Right Grant
-
2000
- 2000-04-28 US US09/560,606 patent/US6265422B1/en not_active Expired - Fee Related
-
2001
- 2001-07-23 US US09/910,967 patent/US6528535B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6265422B1 (en) | 2001-07-24 |
EP0966446A1 (en) | 1999-12-29 |
BR9807674A (pt) | 2000-02-15 |
US6133303A (en) | 2000-10-17 |
AU6170498A (en) | 1998-08-26 |
JP2001518076A (ja) | 2001-10-09 |
KR20000070924A (ko) | 2000-11-25 |
DE69831937T2 (de) | 2006-07-27 |
US6528535B2 (en) | 2003-03-04 |
ATE307119T1 (de) | 2005-11-15 |
WO1998034921A1 (en) | 1998-08-13 |
ES2252827T3 (es) | 2006-05-16 |
DE69831937D1 (de) | 2006-03-02 |
NZ336134A (en) | 2001-08-31 |
EP0966446B1 (en) | 2005-10-19 |
AU725696B2 (en) | 2000-10-19 |
CA2273895A1 (en) | 1998-08-13 |
US20020006936A1 (en) | 2002-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA981080B (en) | Bicyclic inhibitors of protein farnesyl transferase | |
ZA955466B (en) | Stereochemical wortmannin derivatives | |
NZ294933A (en) | Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents | |
CA2322944A1 (en) | Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors | |
UA29446C2 (uk) | Засіб для інгібування тромбіну | |
MX9707192A (es) | Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas. | |
MX9800411A (es) | Compuestos quimicos. | |
MY120090A (en) | Chemical compounds. | |
GR3030354T3 (en) | Substituted arylalkynyl- and heteroarylalkynyl-n-hydroxyurea inhibitors of leukotriene biosynthesis. | |
GR3017996T3 (en) | 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION. | |
NO996578L (no) | Urokinase-inhibitorer | |
AU5320698A (en) | Substituted dihydrobenzofurans as pde inhibitors | |
EP0646007A4 (xx) | ||
MX9602861A (es) | Mezcla estabilizante sinergistica. | |
GB9712966D0 (en) | Novel chalcones | |
AU9066498A (en) | Substituted 6-alkylphenanthridines | |
DE69713524D1 (en) | 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative | |
BG103553A (en) | Benzopyranopyrol and benzopyranopyridine alpha-1 adrenergic compounds | |
PL331347A1 (en) | Derivatives of n-benzene sulphonyl-l-proline | |
HU9501777D0 (en) | Method of treatment of chronic prostatitis with 17-beta-monosubstituted-carbamoly-4-aza-5-alpha-androst-1-en-3-ones | |
AP2000001859A0 (en) | Method for treating multiple sclerosis | |
AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
TW371661B (en) | Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides | |
PL318539A1 (en) | Inhibition of biosynthesis | |
PL317538A1 (en) | Intermediate compound for obtaining a pharmaceutically active compound |